Most Recent

image: Fecal Transplant Pill Fails Trial

Fecal Transplant Pill Fails Trial

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

2 Comments

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Cullen Buie Parses Pathogens With Passion

Cullen Buie Parses Pathogens With Passion

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

1 Comment

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: How to Build Bioinformatic Pipelines Using Galaxy

How to Build Bioinformatic Pipelines Using Galaxy

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Moving Toward Personalized Autism Treatment

Moving Toward Personalized Autism Treatment

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Nailing Down HAR Function

Nailing Down HAR Function

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: On Becoming Human

On Becoming Human

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

1 Comment

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

image: Riboswitch Screen

Riboswitch Screen

By | August 1, 2016

Seres Therapeutics’s microbiome-targeting therapy for recurrent Clostridium difficile infection fails a Phase 2 clinical trial.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech